As of March 31, 2025, the Company had cash, cash equivalents and marketable securities totaling $157.5 million.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics management to meet with Truist
- Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp’s Potential in Treating Friedreich’s Ataxia
- Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
- Larimar Therapeutics should be bought on weakness, says Citi
- Larimar Therapeutics price target raised to $16 from $15 at H.C. Wainwright